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Simon: FDA Reform: The White House View

FDA REFORM: THE WHITE HOUSE VIEW
GREG SIMON*

During a previous speech, I was asked to speak about technology in the
future and address the question, "What does the future hold for society?" To
exemplify the challenges of how we will use our technology, and the type of
society we will have, I chose the emerging science of genetic engineering and
its relationship to the many changes taking place in the digital and computing
world. For example, our understanding of digital processes has enabled us
to further understand the genetic code and the way it works. At the same
time, the knowledge we gain from biotechnology helps us to understand
computers and how to actually grow programs, instead of merely writing
them. We are now able to evolve algorithms inside a computer and take the
process of DNA and put some of that knowledge into a computer and learn
things that we then apply to our studies in biotechnology.

Although we have a long history of thinking of biotechnology as being
alienated with specialized vocabularies, it is important to remember that every

* Greg Simon is the Chief Domestic Policy Advisory to Vice President Al Gore. During
the 1992 presidential campaign, Mr. Simon was Issues Director for Vice President Gore. He
joined Vice President Gore's staff as Legislative Director in March 1991, when the Vice
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Director of the Subcommittee on Investigations and Oversight of the House of Representatives'
Science, Space and Technology Committee, which he joined as counsel in 1985.
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a member of the Washington Law Review and the Moot Court Board and was voted Outstanding
Oralist of the 1983 Northwest Round of the Jessup International Law competition. He is a
member of the Washington State Bar and practiced for two years at the firm of Roberts and
Shefelman in Seattle in commercial litigation and intellectual property.
A native of Arkansas, Mr. Simon attended the University of Arkansas where he was
awarded a B.A. in History, summa cum laude, in 1973. He attended the University of Vienna
in Austria from 1971-1972, studying European diplomatic history in the period between World
War I and World War II.

Published by CWSL Scholarly Commons, 1996

1

California Western Law Review, Vol. 33 [1996], No. 1, Art. 11
CALIFORNIA WESTERN LAW REVIEW

[Vol. 33

aspect of biotechnology has countless implications in many other areas of life.

As biotechnology raises various questions, especially ethical questions, it is
important for us to keep our social vision ahead of our technological
problems. Our decisions about where we as a society wish to go must be as
modem and fresh as our developing technology.

The biotechnology industry has a long history of addressing these
questions head-on, and the topic of FDA reform is a very good nexus point

for discussing how we integrate new technologies with old concerns. In the
case of the FDA, the age-old concern is that the products we give to the
people, what we put out on the street, should be safe, efficacious, and of high
quality. Biotechnology presents a lot of challenges to the regulatory system.

The Clinton administration has tried to address those challenges through many
of the reforms that we have already put into place through our Reinventing
Government initiative.
Last November, the FDA, with Vice President Gore and President
Clinton, announced new measures to reduce costs for the manufacturers of
biotechnology-derived pharmaceuticals to shorten the drug development time
and reduce paperwork.' These measures eliminated the need for approval of
promotional labeling before launching a new product.3 The FDA also

committed to review and respond within thirty days to information that is
responsive to a clinical hold on an investigational4 drug or biologic.' We
eliminated the necessity of an establishment license application for wellcharacterized therapeutic biotechnology drugs.6

We also eliminated the

FDA's lot-by-lot release for well-characterized therapeutic biologic drugs that

1. Remarks Announcing the Report of National Performance Review and Exchange With
Reporters, 29 WKLY. COMP. PRES. DOC. 1700 (Sept. 7, 1993).
2. The measures were announced in the Indian Treaty Room, Old Executive Office Building,
on November 9, 1995. Also present were FDA Commissioner David Kessler and Health and
Human Services Secretary Donna Shalala.
3. See Food and Drug Inst., Reinventing the Regulation of Drugs Made from Biotechnology,
7 FOOD AD DRUG REP. 252 (1996).
4. An investigational drug is one which an Investigational New Drug (M) application has
been filed with the FDA. The application provides the FDA with information on drug
composition, manufacturing data, data on experimental controls, results from laboratory and
animal testing, intended procedures for obtaining consent of subjects and protecting their rights
and an overall plan for human clinical studies. U.S. CONGRESS, OFFICE OF TECHNOLOGY
ASSESSMENT, BIOTECHNOLOGY IN A GLOBAL ECONOMY 249 (1991).
5. Biologics are vaccines, therapeutic serums, toxoids, antitoxins, and analogous biological
products used to induce immunity to infectious diseases or harmful substances of biological
origin. Id. at 268.
6. "Well-characterized" therapeutic biotechnology drugs are therapeutic products whose
"identity, purity, impurities, potency and quality can be determined and controlled." Steve
Sterberg, Three Days of Debate Yields Possible Consensus on FDA Definition for Biotech
Products, Bioworld Today, Dec. 14, 1995, available in LEXIS, NEXIS Library, Magazine file.
Most biotech drugs are in this category.
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are licensed for marketing.' We consolidated twenty-one different forms into
a single format' and allowed biological drug manufacturers to get licenses for
pilot facilities without building full-scale manufacturing plants.
Last March, President Clinton and the FDA announced four new
initiatives to improve patient access to new cancer therapies:
(1)
(2)
(3)

speeding up the approval process by using tumor shrinkage as a
surrogate marker;
expanding patient access to experimental cancer drugs approved in
other countries;
increasing patient representation on cancer drug advisory commit-

tees;
(4)

and making it easier for sponsors to test new uses for cancer

therapies already on the market.9

The driving force behind FDA reform now is the medical device industry and
the progress it has made. In the fiscal year 1995, 98% of the medical device

reviews were completed within 138 days. In the fiscal year 1994, 5,498
7. The lot-by-lot requirements are the result of a traditional distinction made between
biological and non-biological drugs. "Historically, biological drugs-blood and blood products,
vaccines, extracts of natural substances for treating allergies, extracts of living cells and the
like-were treated differently from other drugs because they were often rather impure and the
active substances poorly characterized." Henry I. Miller, FDA is Performing Magic with
"Biological" Drugs, WASH. TIMEs, Nov. 15, 1995, at A15.
Carl Feldbaum, president of the Biotechnology Industry Organization, "noted that the laws
governing biotechs date back to 1912, when Congress cracked down on unscrupulous
entrepreneurs selling horse blood and other bodily fluids as treatments for diseases [such as]
diphtheria." Zachary Coile, Biotech Unbound: Industry Welcomes Overhaul of Drug Approval
Process, S.F. EXAMINER, Nov. 27, 1995, at D1.
These characteristics of biological drugs led the FDA to establish the lot-by-lot requirements
for biologics:
[Since] it was difficult to demonstrate that each batch met specified standards of
purity or potency, the FDA required that the product's sponsor demonstrate a high
level of control over the manufacturing process-every procedure had to be done in a
highly regimented and reproducible way. The regulators granted approval of the
product itself, which had to be safe and effective, and also of the manufacturing
establishment, certifying that there was adequate control and rigor in production. In
addition, samples from every production batch had to be submitted for certification
by the FDA, which analyzed them for purity and potency (to the extent it was
possible).
Henry I. Miller, FDA is PerformingMagic with "Biological" Drugs, WASH. TIMEs, Nov. 15,
1995, at A15.
Non-biological drugs have had no lot-by-lot requirements. The reforms eliminating such
requirements for biologics will harmonize the approval processes for biological and nonbiological drugs.
8. FDA Form 3439, Interim Form for Application to Market a New Drug, Biologic, or
Antibiotic Drug for Human Use, 61 Fed. Reg. 24,313 (1996). The format was not released at
the time these measures were released. The proposed revised format was expected within six
months from November 1995.
9. President's Remarks on the Anticancer Initiative, 32 WKLY. CoMP. PRES. Doc. 587 (Mar.
29, 1996).
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reviews were completed in 182 days. In one year, the FDA went from
approximately 5,500 reviews taking 182 days to roughly 5,600 reviews taking
138 days or less.
Considering the volume of devices involved here, and their impact on our
health care system, an increase of 25% in one year for 98% of medical
devices is a significant improvement. To further this improvement, we
developed a pilot program to review low to moderate risk medical devices by
outside organizations and expanded 125 categories of low-risk medical
devices exempt from pre-market review.
In terms of FDA drug approvals in 1995, 82 new drugs were approved
in 162 months (median) compared with 62 new drugs approved in 19 months
the year before. Twenty-eight of the 1995 approvals were for entirely new
drugs, not new formulations of existing drugs. Fifteen of the 1995 approvals
were priority drugs" and were approved in 6 months, compared with 17
priority drugs approved in 15 months the year before. In October of 1995,
the General Accounting Office (GAO) reported that the FDA approval times
for priority drugs were shorter in the United States than they were in the
United Kingdom and that the median approval time for new drugs in calendar
year 1994-1995 in the United States was the same as that in Britain and faster
than that in France, Spain, Germany, Australia, Japan, Italy, and Canada."
Yet progress is not the end of the story-it is merely the beginning. The
question now is, "Where does FDA reform go from here?"
It is important to first summarize the goals of FDA reform. There are
many ways to reform, but we have always first supported reform that builds
on the progress we have already made in expediting the review of drugs,
therapeutics, and devices as quickly as possible while meeting the standards
that the FDA is charged by law to meet. The American public has a right to
expeditious pharmaceutical approvals, while being confident in the safety and
efficacy of the drugs, devices, and therapeutics that come on to the market.
Reform should not be dismantled; neither should it choke someone to
death. Therefore, we have asked for the types of resources that the FDA
needs to get the job done. Everybody knows that the improvement in
pharmaceutical reviews came about because of the Drug Fee User Act: the
ability to channel industry resources to the FDA, which is then more able to
efficiently and speedily review new drugs and therapeutics with greater
resources. The industry once supported a device user fee, but such support
has recently disappeared. Thus, the question arises, if we do not put more
resources into device review at the FDA, how can we reform it? What can

10. "A priority drug is one that the FDA determines to represent a significant therapeutic
advance either offering important therapeutic gains (such as the first treatment for a condition)
or reducing adverse reactions." GAO REPORT: FDA DRUG APPROVAL-REVIEW TIME HAS
DECREASED IN RECENT YEARS, at 37 (1995) [hereinafter GAO Report].
11. Id.at 80-81.
12. Prescription Drug Establishment, and Prescription Drug Product Fees, Pub. L. No. 102571 § 106, Stat. 4491 (1992) (codified at 21 U.S.C. § 301).
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we do to address the concerns that the biotechnology industry has about the
review of biotechnology products?

First, we fully support legislating any of the reforms that we have put in
place through the Reinventing Government initiative.

We were able to

implement most of the Reinventing Government initiative reforms administratively, 3 but people who worry about the vacillation from one administration

to the next prefer that these reforms be in statutory language. This is not
really a problem-these reforms will continue for everyone over whom we
have the executive power of implementation. 4
I point out also that the exportation of unapproved drugs was approved
and increased in the recent budget in a way we support. The FDA did this
by expanding the philosophy that before a drug which has not yet been
approved in the United States can be exported, it must be approved by both
the importing country and another country that has a recognized system of
pharmaceutical review with certain standards they were forced to meet.'

Those countries had been listed in statute 6 for a long time. The bill allows

expedited export if one of those listed countries has approved it and it has
been approved by the importing
country, though there are some exceptions
7
and waivers that add to that.'

13. Some representative regulations changes in this reform are: 21 C.F.R. pts. 600, 601, 620,
630, 640, 650, 660, 680, 801, 862, 866, 870, 872, 874, 876, 878, 880, 882, 884, 886, 888, 890,
and 892 (1996).
14. There is a problem in implementation. Even with the best of staffs, how do you go
from the rules to the implementation? As Truman said when Eisenhower was elected, "I can't
wait for this general to come into the Oval Office, pick up the phone, bark an order and put it
down and nothing happens." That is what happens in a large bureaucracy. We have a large
bureaucracy because we have a large country, and we have a lot of things to do, especially at the
FDA. I am amazed at the volume of work the FDA has. We are fighting very hard to send the
message down the chain in terms of the attitude we expect from professionals and the kind of
customer service we expect. We have made a lot of progress, but we still have a long way to
go.
15. 21 U.S.C. § 382(b)(1) (1996) (amending 21 U.S.C. § 382(b)(1) (1994)). This section
was amended April 26, 1996.
16. 21 U.S.C. § 382(b)(1) (1994), amended by 21 U.S.C. § 382(b)(1) (1996). The previous
version of the statute specified approved countries for drug exportation. Those countries were
Australia, Austria, Belgium, Canada, Denmark, Federal Republic of Germany, Finland, France,
Iceland, Ireland, Italy, Japan, Luxembourg, the Netherlands, Norway, Portugal, Spain, Sweden,
Switzerland, and the United Kingdom.
17. The current version of the statute provides for exportation if the drug or device complies
with the laws of that country to which the drug or device is being exported and if the drug or
device has been approved by Australia, Canada, Israel, Japan, New Zealand, Switzerland, South
America or in the European Union or European Economic Area. Unlike the prior version, the
current version provides for direct importation if the criterion are met and does not require an
application and approval process. However, the exporter must notify the FDA when it first
begins importation and must maintain records of the drugs/devices and the countries to which
they were exported.
Exceptions and waivers include the following:
1. A drug or device intended for investigational use in any listed country may be exported
in accordance with the laws of the country and are exempt from regulation. 21 U.S.C. §
382(c) (1996).
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We support the current legislative debate reforms that would incorporate
performance standard approaches to the way that drugs and devices are
reviewed: expediting the marketing of drugs and devices for serious

conditions; contracting-out of FDA inspections that occur; reduction and, in
some cases, elimination of environmental impact statement requirements in
areas where there has never been any environmental impact noted or even
suspected; and exempting many of the less dangerous devices from pre-

market review by the FDA."
What we have opposed in Senator Kassenbaum's (R-KS) legislation,

9

and what we are currently negotiating with many members of the Congress,
is the idea that we utilize quick review as a trigger for contracting-out or
other changes in the way we review drugs intended for the marketplace. In
the vernacular, this is referred to as "the hammer." The hammer works as
follows: If the FDA does not review a certain percent of drugs within a
certain amount of time, they are forced to contract-out and have someone else
do it. One problem with the hammer is that many of those review times are

less than the times that are listed in the Drug Fee User Act,2" which was a
compromise reached between the government and the industry.

Another problem is the concept that you would punish a regulatory
agency for not meeting a statutory deadline and contracting-out when you are

not providing the resources necessary to meet those deadlines. Everybody

2. A drug or device intended for formulation, filling, packaging, labeling or further
processing the anticipation of market authorization in any listed country may be exported
for use in accordance with the laws of that country. 21 U.S.C. § 382(d) (1996).
3. Exportation of a drug or device used in the diagnosis, prevention or treatment of a
disease which is not prevalent in the United States requires prior approval. 21 U.S.C, §
382(e) (1996).
4. A drug or device may not be exported if the drug or device:
(a) is not manufactured, processed, packaged and held in substantial conformity
with current good manufacturing practice requirements; or
(b) does not meet international standards; or
(c) is adulterated; or
(d) is likely to be re-imported; or
(e) presents an imminent hazard to the people of the country to which is it being
exported; or
(f) is not properly labeled.
21 U.S.C. § 382(f) (1996).
5. In any event though, the FDA will notify the country to which the drug is being
exported if an application for new drug (21 U.S.C. § 355), pre-market approval (21 U.S.C.
§ 360(e)), or for exportation of partially processed biologic products (42 U.S.C. § 262) was
disproved. 21 U.S.C. § 382(a)(2)(2) (1996).
18. S. 1477, 104th Cong., 1st Sess. (1995).
19. Id.
20. Approval times vary, depending on the type of drug or device: 180 days for new drugs
(21 U.S.C. § 355), new animal drugs (21 U.S.C. § 360(c)), and pre-market approval for Class
III devices (U.S.C. § 360e(d); 120 days for product development protocol (21 U.S.C. § 360d(f));
and 90 days for intended use of animal fee containing new animal drug (21 U.S.C. § 360b(m)).
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knows that there is a mismatch between the demand and the resources. This

is not just unfair in general, but it is a dangerous way to do business." The
concept of contracting-out for private review of therapeutics and drugs
devised for public consumption raises a question: If people are so willing to
pay a third party to do it, why aren't they willing to pay the FDA to do it?
This is certainly the case with regard to devices. If people are willing to pay
a third party to review a device, why aren't they willing to set up a user fee
system to have the government do it? At this time, we are not proposing a
user fee for devices because that debate is over; however, we are proposing
to remove the "hammers" from the bill and talk about real ways to improve
the long-term health of the review process. The long-term health is not

served by looking at what happens during the next six months and then what
happens during the six months after that.

We do not believe that if a foreign government approves a drug, that
drug should automatically go to the head of the line in the United States.

That is a dangerous way to organize our priorities. Our priorities ought to be
the health and safety of the drugs that are provided to the American public.
If other countries with smaller populations and smaller government burdens
are able to review some drugs more quickly than others, that is terrific for

those companies; but our priorities should be those which we set, not those
dictated by foreign governments. We have a difficult time with the idea that
we should force our decisions based on what other people are doing.22
We also have concerns over eliminating all the requirements to notify the

FDA of certain changes to manufacturing processes.'

As Yogi Berra once

said, "It's not the things you don't know that get you in trouble, it's the

things you know for sure that just ain't so." When people are certain that
21. This raises a troubling point about the experience of reviewers. It is very difficult,
especially in the current environment, to get people to stay in public service when they can have
such lucrative careers in the biotechnology or the pharmaceutical industries. If they stay in the
public service, they get beaten up every day in the Congress; they get blasted in the press; good
work is seldom noted in public. It is simply not a glorified place to work. It has a lot of
meaning, and there are a lot of devoted people who will be there for years and years, but until
we give the professionals in the government the kind of compensation and respect that they
deserve, we will constantly have people seeking better opportunities in the private industry.
22. This is not to say that we are not actively pursuing harmonization and the expedited
approval that comes with harmonization of data. The difficulty is that the House bill requires
a drug to go to the top of the line at the FDA if it has been approved by another country.
Requiring the FDA to suddenly stop what it is doing based on its priorities and take a drug and
review it within a certain time frame after its approval in another country is a different question.
We totally support the ability to expedite approval through the harmonization of data. In addition
to that, the approval of a drug in another country does have an impact on our export rules, under
the new changes that were recently made. Harmonization is the goal, but to move something to
the top of the list because it has been approved in another country really steps into the decision
at the FDA about what constitutes a priority. This is a decision that we should not leave to other
countries.
23. Currently, each application for a new drug requires a full description of the manufacturing process. 21 U.S.C. § 355(b)(1)(D) (1994). Any change to an approved application requires
notice to the FDA, either through a supplemental application or in the annual report to the
application. Furthermore, FDA approval of the supplemental application is required before any
changes can be made. 21 C.F.R. § 314.70 (1996).
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their change is .safe, that is exactly the time when they should get a second
opinion. Of course, companies do not get a second opinion for every change
they make. We have proposed certain guidelines about the kinds of changes
that need to be reviewed-but the concept that we can expand the exemption
of pre-market review of certain changes in manufacturing ignores the history
of changes both in the vaccine area and in the device area. These changes
have had significant impacts on human health or might have, had the FDA
not reviewed them.
The topic of off-label uses is very complicated and affects the biotechnology industry directly, but is not currently in the Senate bill. There is a
balance of interests here that requires a lot of thought on both sides. There
is an argument that goes as follows: If a respected journal publishes a trial
that shows a use for an improved product not currently on its label, and that
information is helpful in the practice of medicine, the information should be
widely disseminated. This argument has a lot of surface appeal, and the law
does not prevent a doctor from finding out about those uses. It does, however,
prevent people from publishing those uses to a mass audience as a way of
advertising or otherwise disseminating information about an off-label use.24
From the government's perspective as the guardian of public health, the
concern is that the dissemination of off-label uses becomes a back-door way
to approving other uses for a drug that may have been too difficult to get
approval for initially. A company gets the drug approved for its easiest use.
It then uses a study or two published in a journal to market it in the practice
of medicine for other uses and never submits that information to the FDA.
The other concern is that there are often situations in which suggested
uses for approved drugs and devices prove beneficial in one study, but
competing studies show the opposite. There is no obligation for a company
to disseminate all the studies conducted. This argument may not be
resolved-both sides have very good cases. Both sides have important
interests involved and we are hoping to reach an agreement directly with the
industry and the FDA. Another alternative is to legislate an off-label policy
that encourages people to submit the new data and efficacy supplements to
the FDA. In exchange for this data, they would be able to distribute the
information from certain prestigious journals to practitioners of medicine.
The legislation pending on the Hill is very different in both tone and
extent. The House has broken up the legislation into several different

24. An advertisement for a prescription drug covered by a new drug application shall not
recommend or suggest any use that is not in the labeling accepted in such approved drug
application or supplement. 21 C.F.R. § 202.1(e)(4) (1996).
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pieces,25 unlike the Senate has the Kassenbaum bill, which is supported by
a number of prominent Democrats with whom we are currently consulting.
I would like to give you a bright-line example that demonstrates the point
about why we think FDA reform is important, but also serious enough that

we want to do it right if we are going to do it at all. This bright-line
example is the area of third party review of medical devices.

The Clinton Administration proposed a pilot project for third party

review of medical devices.26 The Kassenbaum bill initially had a very similar

pilot project that did not include Category Three devices.27 Senator Wellstone
(D-MN), who is very interested in this issue, did not include Class Three
medical devices in his earlier legislation.2" In the Senate committee mark up,
Senator Coats (R-IN) offered an amendment to include Category Three
devices, and the amendment passed.29 This is an area where a compromise

25. 1. The FDA Modernization Act of 1995 was introduced June 6, 1995 by Rep. Ron
Wyden (D-OR). The purpose of the bill is to revise the drug approval process and for other
purposes. H.R. 1742, 104th Cong. 1st Sess. (1995).
2. The Life Extending and Life Saving Device Act of 1995 was introduced September 8,
1995 by Rep. Jon D. Fox (R-PA). The purpose of the bill is to amend the medical device
provisions of the Federal Food, Drug, and Cosmetic Act. H.R. 2290, 104th Cong. 1st Sess.
(1995).
3. The Medical Device Reform Act of 1996 was introduced March 29, 1996 by Rep. Joe
L. Barton (R-TX). The purpose of the bill is to facilitate development, clearance, and use of
medical devices to maintain and improve public health and quality of life. H.R. 3201, 104th
Cong. 2d Sess. (1996).
26. On April 6, 1995, the Clinton Administration announced a two-year pilot program to
determine if third party review of low to moderate risk medical devices could speed up review.
The FDA announced implementation of such a program where the third party would make
recommendations to the FDA, but the FDA still makes the final determination. 60 C.F.R. 28617
(1996).
27. Category Three devices are Class III Devices as defined in 21 U.S.C. § 360c (1994).
Class III devices are devices intended for human use, and which require pre-market approval.
Class I devices (general controls) are devices which the controls indicated in sections 351,
352, 360, 360(0, 360(h), 360(i), 360j) are sufficient to provide reasonable assurance that the
device is safe and effective. These devices are not used in supporting or sustaining human life
and do not present a potential unreasonable risk of injury or illness. 21 U.S.C. § 360c(a)(1)(A)
(1994).
Class II devices (special controls) are devices which cannot be classified as Class I because
the controls are insufficient to determine safety or effectiveness, but for which there is sufficient
information to establish "special controls" to provide such assurance. Such "special controls"
include performance standards, postmarket surveillance, patient registries, development and
dissemination of guidelines (for submission of clinical data), and recommendations necessary to
assure safety and effectiveness of the devices, especially devices used in supporting or sustaining
human life. 21 U.S.C. § 360c(a)(1)(B) (1994).
Class III devices (pre-market approval) are devices which (1) cannot be classified as Class
I or Class II because of insufficient available information, and (2) are to be used in supporting
or sustaining human life or in preventing impairment of human health, or which present
unreasonable risk of injury or illness. Class III devices are subject to premarket approval to
provide reasonable assurance of its safety and effectiveness. 21 U.S.C. § 360(c)(a)(1)(C) (1994).
28. S. 1369, 104th Cong., 1st Sess. (1995). This bill was introduced on October 31, 1995
and sent to the Senate Labor and Human Resources Committee that same day. No further action
has been taken on that bill at the time of publication.
29. Senator Coats offered an amendment to S.1477 in the Senate Labor and Human
Resources Committee. The Committee approved the amendment by a vote of 11-4 on March 28,
1996. S. REP. No. 284, 104th Cong., 2d Sess. (1996).
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is possible and necessary. We do not think that you save either resources or
time by contracting-out to private parties who would be paid by the company
seeking approval for devices that are so serious that any deficiency in the
review could lead to the loss of a single life. It will not save either time or
money because the FDA would review the review.
When you are dealing with a life-saving device, to review the review is
basically to do the review again. There is no such thing as just checking the

bottom line to see if it looks good. This is not a case of a "performance"
standard that one can meet with some objective criteria. This is a case of the

efficacy standard and whether something has a proper impact on saving or
prolonging human lives."
So, what is a possible compromise? We have proposed that if you want
to save resources that can be applied to Class Three devices within the FDA,
you should limit the pilot project to Class One and Class Two." We would

like to expand the Class Two definition to include devices that can be
reviewed based on safety and performance. Category Three would be
comprised strictly of devices that need to be reviewed for safety and efficacy.

By using or contracting-out the resources to review Class Two, where there
is a performance standard to meet, you free up resources that the FDA can
apply to Class Three without having to do the review twice to ensure that

serious medical devices are not going into the market without a thorough,
objective review by a disinterested party.

I refer to this as a bright-line test about the kind of reform we ought to
have. We can have reform that accomplishes both industry and government
goals with some of these compromises: on-label and off-label uses; the
contracting-out of medical devices; manufacturing changes; and pre-market

notification. These changes, taken in conjunction with the changes that we
announced in the Reinventing Government initiative, can make a reform
package that has meaning, and which can be passed this year.

30. The logical question at this point is, "If some of these reforms come about, what
happens with regard to the liability issue if you were to have another thalidomide experience,
where a product was approved and caused harm, but it was approved either by going to the top
of the line or under one of these expedited third party reviews?" I am no liability expert, but
our job is to avoid that problem. The reforms that we would accept would be reforms that still
give the FDA the ultimate authority to protect the health and safety of the public. In the past,
and in the product liability bill, we have opposed the granting of immunity to a product because
it had received approval by a government agency-whether it was the FDA or another agency-on
the grounds that every product that is approved has a post-market surveillance period as well.
Now we pride ourselves in having a far lower rate of recalls based on post-market surveillance
than does Europe, which although it approves some things more quickly, has to call back a lot
more things than we do.
The liability questions remain and should be sobering concerns for people who want to
speed up the front end, but forget that the post-market surveillance is an area we also have to be
concerned about. We must keep the recalls at a minimum and not have to answer to the
American public for irresponsible or too expedited reviews that didn't take into account all
available information. All available information does not always give you everything you're
going to know after a couple of years on a mass market. We try to move very quickly in those
cases.
3 1. See supra note 27.
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Passing any bill is a challenge; many are proposed, few pass. We view
the House bills at this point as being too far beyond the line that we can
accept, for many reasons which I am sure you have heard in recent testimony.32 We prefer to start with the Kassebaum bill and if we can make the
compromises regarding the "hammers" and the medical devices, we believe
that this is a vehicle that can move. If those changes cannot be made, then
we would rather wait and do it right than to hurry up and have to do it again
because we would have a difficult time taking the steps beyond the lines that
we think are fair.
We are not afraid of criticism of the FDA. We have ourselves criticized
the FDA, and we have been very aggressive in changing the FDA. We have
been very aggressive in changing the executive branch via the Reinventing
Government program. We have tried to make the entire government more
user-friendly, online, and more responsive, but the public asks us to protect
them from certain things. If there is ever a clear function of government, it
is for the FDA to make sure that our foods, drugs, and devices are safe. This
does not mean that review must be slow, expensive or tedious, but it does
mean it has to be careful and disinterested.
Many of the critics of the FDA are criticizing it because they would
prefer that most of it go away. Some groups have even suggested that we
remove from the mission statement of the FDA the task to protect the public
health and safety, and focus instead on the quick and expeditious review of
drugs, devices, and foods. This is not only beyond the line, but beyond the
pale. As Abraham Lincoln once said, "He has a right to criticize who has a
heart to help."
The biotechnology industry has had a heart to help. They have been
front-and-center in helping us devise many of the reforms we announced in
the Reinventing Government initiative and in very productive discussions with
the Administration on the types of changes we can make in the legislation.
But this is not just a case of if we do it wrong this time, when are we going
to have the time to do it again? This is a case where we cannot afford not
to do it right the first time because we do not want to have to go through the
pain we would go through to find out that we have to do it over. That is
why we support careful, deliberative reform and will oppose any reform that
does not meet those standards.

32. FDA Approval Process: David A. Kessler, M.D. Commissioner of Food and Drugs
Department of Health and Human Services Before the Subcommittee on Health and Environment,
104th Cong., 2d Sess. (1996) (statement of David Kessler, M.D., Commissioner, FDA).

Published by CWSL Scholarly Commons, 1996

11

California Western Law Review, Vol. 33 [1996], No. 1, Art. 11

https://scholarlycommons.law.cwsl.edu/cwlr/vol33/iss1/11

12

